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Background. Persons infected with human immunodeficiency virus (HIV) are at higher risk for major cardiovascular disease
(CVD) events than uninfected persons. Understanding the epidemiology of major traditional CVD risk determinants, particularly
hypertension, in this population is needed.
Methods. The study population included HIV-infected patients participating in the UNC CFAR HIV Clinical Cohort from 1996
to 2013. Annual incidence rates of hypertension were calculated. Multivariable Poisson models were fit to identify factors associated
with incident hypertension.
Results. 3141 patients contributed 21 956 person-years (PY) of follow-up. Overall, 57% patients were black, 28% were women, and
the median age was 35 years. Hypertension age-standardized incidence rates increased from 1.68 cases per 100 PYs in 1996 to 5.35 cases
per 100 PYs in 2013 (P < .001). In adjusted analyses, hypertension rates were higher among obese patients (incidence rate ratio [IRR]
1.70, 95% confidence interval [CI], 1.43–2.02), and those with diabetes mellitus (IRR 1.44, 95% CI, 1.14–1.83) and renal insufficiency
(IRR 1.36, 95% CI, 1.16–1.61), but lower among patients with a CD4 nadir of ≥500 cells/mm3 (IRR 0.73, 95% CI, .53–1.01).
Conclusions. The incidence of hypertension increased from 1996 to 2013, alongside increases in traditional hypertension risk de-
terminants. Notably, HIV-related immunosuppression and ongoing viral replication may contribute to an increased hypertension risk.
Aggressive CVD risk factor management, early HIV diagnosis, linkage to care, antiretroviral therapy initiation, and durable viral sup-
pression, will be important components of a comprehensive primary CVD prevention strategy in HIV-infected persons.
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Cardiovascular disease (CVD) is a leading cause of death
among persons infected with human immunodeficiency virus
(HIV) in North America and Europe [1, 2]. With aging of the
HIV-infected population as a whole, the incidence of major car-
diovascular events (eg, acute coronary syndromes, stroke),
strongly associated with advancing age, will likely continue to
rise. In addition to the expected increases in major CVD events
among HIV-infected persons given changing population demo-
graphics, evidence also suggests that HIV infection itself may
contribute to an increased risk of major CVD events [3, 4].
For these reasons, improving our understanding of the epidemi-
ology of established CVD risk determinants in HIV-infected
persons, and how these determinants impact cardiovascular
health in the context of the chronic immune activation unique
to HIV infection is of heightened importance.
Hypertension is an “established” CVD risk factor affecting
22% of adults worldwide, contributing to over 7.5 million
deaths annually [5]. Despite its prevalence in the general popu-
lation, hypertension among HIV-infected persons has not been
well characterized. Reports assessing hypertension among HIV-
infected patients are available prior to the use of contemporary,
metabolically safer antiretroviral therapy (ART) [6–10].Wheth-
er the epidemiology of hypertension has changed in more re-
cent years with availability of more potent and well-tolerated
ART and longer-term survival remains unclear. Therefore, the
objectives of this study were to characterize the annual inci-
dence rates of hypertension and identify patient characteristics
associated with hypertension using a well-characterized HIV
clinical cohort from 1996 through 2013.
METHODS
Study Population
All HIV-infected patients participating in the UNC Center for
AIDS Research HIV Clinical Cohort (UCHCC) between 1 Janu-
ary 1996 and 31 December 2013 were included in the study. The
UCHCC collects comprehensive and granular data from institu-
tionally available electronic health and administrative records
and performs expansive medical record reviews. The data cover
demographic factors, clinical diagnoses, laboratory findings, and
medication provision. Comprehensive details of the UCHCC
have been described previously [11]. Of the eligible 4290 patients
Received 17 December 2015; accepted 3 April 2016; published online 18 April 2016.
Correspondence: N. L. Okeke, Hanes House Rm 154, 315 Trent Dr, Durham, NC 27110 (lance.
okeke@duke.edu).
Clinical Infectious Diseases® 2016;63(2):242–8
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society
of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
DOI: 10.1093/cid/ciw223
242 • CID 2016:63 (15 July) • HIV/AIDS
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/63/2/242/1745207 by U
niversity of N
orth C
arolina at C
hapel H
ill H
ealth Sciences Library user on 13 August 2019
receiving care in the study period, we excluded 678 patients with
missing data for key analysis covariates, including unavailable
vital signs (n = 193) and CD4 count (n = 474). Overall, 3612
were included in the baseline analysis. The UNC Institutional Re-
view Board approved the study protocol.
Hypertension
The primary outcome of interest was incident hypertension
defined as having a documented diagnosis of hypertension with
a diagnosis date at least 90 days after start of follow-up. All persons
diagnosed with hypertension prior to 90 days after entry into HIV
care at UNC were excluded from the final study cohort. Only hy-
pertension documented by the provider (regardless of available
ambulatory blood pressures) was used to determine the outcome
diagnosis. All diagnoses of hypertension were reviewed based on
the clinical record. The date of diagnosis was the date determined
by the clinician that the patient met criteria for hypertension.
Covariates
We included data on basic demographics (age, sex, race/ethnicity),
insurance status, behavioral risk determinants (alcohol, tobacco),
CVD risk diagnoses (hyperlipidemia, diabetes, renal insufficiency),
anthropomorphic data, HIV transmission risk factors (men who
have sex with men [MSM], IV drug use), detailed substance
abuse history, Hepatitis C co-infection and ART use, collected at
baseline. Hyperlipidemia, diabetes and Hepatitis C were by the
provider-documented diagnosis in the medical record. HIV viral
loads (VLs) and CD4 nadir reported in the analysis were based
on values obtained prior to an incident event (or the end of fol-
low-up). Obesity was defined as a body mass index ≥30 kg/m2.
Renal insufficiency was defined as a maximum creatinine of
≥1.4 mg/dL. ART duration was defined as the time from ART ini-
tiation until end of follow-up. HIV-1 VL suppression was defined
as two consecutive VL measures <400 copies/mL.
Statistical Methods
Patients were followed from the latter of first clinic visit or 1 Jan-
uary 1996 (baseline) until an incident hypertension diagnosis,
loss to follow-up (defined as no clinical visit for 18 months),
death or administrative censoring (31 December 2013). Demo-
graphic and clinical characteristics of patients with and without
prevalent hypertension at baseline were compared using
Wilcoxon-Mann–Whitney test for continuous variables and Pear-
son’s χ2 for categorical variables. We estimated hypertension inci-
dence rates by taking the number of events divided by person-
time, and calculated 95% confidence intervals (CI) based on a
Poisson distribution. For the analysis of incident hypertension
by year of diagnosis, calendar year incidence rates were standard-
ized to the age distribution of the analysis cohort at the midpoint
of observation.
Unadjusted and adjusted incidence rate ratios (IRRs) and mea-
sures of precision were estimated using Poisson regression. Addi-
tional models were fit with interaction terms for key covariates to
test for effect measure modification. Models with and without
interaction terms were assessed for goodness-of-fit using likeli-
hood ratio tests and by comparing Akaike information criteria
for each model. A P-value <.1 for interaction was considered stat-
istically significant, and an alpha of 0.05 was used for all other
statistical hypothesis testing. All analyses were performed using
SAS software, Version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
Study Population
Overall, 3612 cohort members were eligible for analysis. The
median age of the group was 36 years (interquartile range
[IQR] 29–44). Seventy-one percent of these patients were
male, 59% were non-Hispanic Blacks, 41% were MSM, and
42% were uninsured. The median CD4 nadir for the entire
cohort was 173 cells/mm3 (IQR 38–360). Forty-one percent of
patients were current or former tobacco users, and 18% were
coinfected with hepatitis C (Table 1).
At baseline analysis, 471 patients had a documented diagno-
sis of hypertension. Patients with prevalent hypertension at
baseline were older, more likely women, and non-Hispanic
black, than those without prevalent hypertension (all P < .01)
(Table 1). Patients with hypertension at baseline were also
more likely to be obese (31% vs 18%), have hyperlipidemia
(27% vs 16%), and have diabetes (16% vs 5%) (all P <.01).
The 3141 patients without hypertension at baseline contributed
21 956 person years (PY), with a median follow-up time of 5.5
years (IQR 2.7–10.0). The median nadir CD4 during follow-up
was 168 cells/mm3 (IQR 36–352), and the median CD4 at time
of hypertension diagnosis or end of follow-up was 436 cells/
mm3 (IQR 208–682) (Table 2). Fifty-nine percent of patients
were virologically suppressed at end of follow-up; the median
time of ART exposure was 4.8 years (IQR 2.2–9.0 years) (Table 2).
By the end of the study period, 612 patients died, 942 were lost to
follow-up, and 756 cases of incident hypertension were diagnosed.
Hypertension Incidence by Calendar Year
The crude incidence rate of hypertension was 3.44 cases per 100
PYs (95% CI, 3.20–3.70). Overall, unadjusted hypertension in-
cidence rates were observed to increase across calendar years
from 1996 to 2010 (p for trend = 0.002 Figure 1). The incidence
rate was 1.68 cases per 100 PYs in 1996 rising to 5.98 cases per
100 PY in 2010 and subsequently falling to 5.38 cases per 100
PYs in 2013. Similar results were observed for age-standardized
annual estimates (p for trend = 0.02; Figure 2).
Duration of Antiretroviral Therapy at Time of Hypertension Diagnosis
During the study period, 90% of all study participants were ini-
tiated on ART. The median duration of ART use was 4.8 years
[IQR 2.2–9.1] prior to the end of study follow-up. Among per-
sons eventually diagnosed with hypertension, the median dura-
tion on ART prior to diagnosis was 4.3 years [IQR 1.7, 8.4].
When cohort members were stratified by duration of exposure
to ART, persons who were on ART for 5 years or more had the
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highest incidence rates of hypertension (age-adjusted IR 11.16
cases per 100 PY; 95% CI, 9.91–12.41). Hypertension incidence
rates were lowest among persons who never started ART (age-
adjusted IR 0.95 per 100 PY; 95% CI, .71–1.18). To assess
whether total duration in care influenced ART-exposure strati-
fied hypertension IRs, we determined hypertension IRs by total
Table 1. Patient Characteristics Stratified by Hypertension at Baseline
Characteristic All Patients (n = 3612) No Hypertension (n = 3141) Prevalent Hypertension (n = 471) P Value
Age (y), median (IQR) 36 (29–44) 35 (29–42) 43 (36–49) <.001
Male sex, n (%) 2575 (71) 2269 (72) 306 (65) .002
Race/ethnicity, n (%) .01
White, non-Hispanic 1141 (32) 1018 (32) 123 (26)
Black, non-Hispanic 2133 (59) 1800 (57) 333 (71)
Hispanic 212 (6) 208 (7) 4 (1)
Other 126 (3) 115 (4) 11 (2)
Insurance, n (%) .46
Medicare/Medicaid 1072 (30) 917 (29) 155 (33)
Private 1081 (30) 940 (29) 141 (31)
Uninsured 1519 (42) 1344 (42) 175 (36)
Body mass index (kg/m2), Median (IQR) 23.6 (21.7–25.8) 23.1 (21.7–25.2) 25.3 (21.9–28.5) n/a
Serum creatinine (mg/dL) 0.9 (0.8–1.0) 0.9 (0.8–1.0) 1.0 (0.8–1.2) .03
Ever tobacco use, n (%) 1495 (41) 1355 (43) 140 (30) <.001
Alcohol abuse, n (%) 1037 (29) 926 (29) 111 (24) .01
Hyperlipidemia, n (%) 645 (18) 518 (16) 127 (27) <.001
Diabetes, n (%) 243 (7) 167 (5) 76 (16) <.001
Hepatitis C, n (%) 636 (18) 552 (18) 84 (18) .89
ART exposed 3266 (90) 2836 (90) 430 (91) .49
MSM 1467 (41) 1311 (42) 156 (33) <.001
IVDU 488 (14) 412 (13) 76 (16) .07
Cocaine use 1068 (30) 943 (30) 125 (27) .12
Amphetamine use 141 (4) 128 (4) 13 (3) .16
CD4 nadir, cells/mm3, median (IQR) 173 (38–360) 168 (36–352) 200 (61–390) n/a
All characteristics measured at baseline.
P-values were calculated using Wilcoxon-Mann-Test for continuous variables and Pearson’s χ2 for categorical variables.
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; IVDU, intravenous drug use; MSM, men who have sex with men; n/a, not applicable.
Table 2. Clinical Characteristics During Follow-up Stratified by Incident Hypertension
Characteristic All Patients (n = 3141) Hypertension (n = 756) No Hypertension (n = 2385)
BMI maximum, kg/m2
Median (IQR) 27.7 (24.5–30.2) 28.5 (25.4–33.1) 27.5 (24.2–29.5)
>30, n (%) 859 (27) 308 (41) 551 (23)
BMI meana, kg/m2
Median (IQR) 26.2 (22.7–28.7) 26.8 (23.6–30.3) 25.9 (22.3–28.3)
>30, n (%) 565 (18) 209 (28) 356 (15)
Creatinine maximum ≥1.4, n, (%) 708 (23) 230 (30) 478 (20)
Creatinine most recent ≥1.4, n (%) 232 (7) 78 (10) 154 (6)
CD4 nadir, cells/mm3
Median (IQR) 168 (36–352) 153 (30–325) 175 (38–362)
CD4 most recent, cells/mm3
Median (IQR) 436 (208–682) 446 (266–664) 433 (190–688)
HIV-1 VL most recent, <400 copies/mL, n (%) 1859 (59) 485 (64) 1374 (57)
Ever on ART, n (%) 692 (92) 2144 (90)
ART exposure (y)b, Median (IQR) 4.80 (2.21–9.01) 4.95 (2.38–9.15) 4.26 (1.74, 8.41)
PI use ever, n (%) 2774 (88) 685 (91) 2089 (88)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; PI, protease inhibitor; VL, viral load.
a Average body mass index over follow-up period.
b Among persons initiated on ART.
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duration of follow-up. Persons who were followed for 5 years or
more had higher age-adjusted incidence rates or hypertension
than persons who were observed for 2 years or less (4.62 vs
3.36 cases per 100 PY; Table 3). However, the variation in IRs
by ART exposure strata was stronger than the variation in IRs by
follow-up time strata.
Factors Associated With Incident Hypertension
In multivariable analyses, for every 10 year increase in age at
start of follow-up, there was a 34% increase in the incidence
rate of hypertension (IRR 1.34, 95% CI, 1.24–1.44) (Table 4).
Persons who met criteria for obesity at the time of study entry
were diagnosed with hypertension at a significantly higher rate
than persons who were not obese (IRR 1.70, 95% CI, 1.43–2.02).
Renal insufficiency and diabetes were also significant risk deter-
minants for incident hypertension (IRR 1.36, 95% CI, 1.16–
1.61, and IRR 1.44, 95% 1.14–1.83, respectively). There was a
trend toward increased incidence of hypertension in blacks
(P = .10), and sex was not associated with incident hypertension
(P = .76).
After adjusting for the aforementioned hypertension risk fac-
tors, we observed a strong trend toward a lower incidence in hy-
pertension among patients with high CD4 nadirs (≥500 cells/
mm3) (IRR 0.73, 95% CI, .53–1.01). We also observed a trend
Figure 1. Annual unadjusted hypertension incidence rate with trendline by calendar year. Solid line is the annual unadjusted incidence rate; 95% confidence intervals are
shaded area, and dotted line is the linear regression line with slope of 0.17. Abbreviation: PY, person years.
Figure 2. Age-adjusted incidence rates and 95% confidence intervals of hypertension stratified by calendar year- 1996–2013. *Standardized to the age distribution at the
midpoint of participant follow-up. Abbreviation: PY, person years.
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toward decreased hypertension incidence among persons with a
suppressed HIV-1 VL (P = .11) and persons not exposed to pro-
tease inhibitors (P = .12) (Table 4).
DISCUSSION
CVD has emerged as a leading cause of mortality among
HIV-infected persons, yet our understanding of key CVD risk
determinants in this population is inadequate [1, 2]. In a well-
characterized clinical HIV cohort, we observed that many of the
traditional risk factors for hypertension in uninfected persons
(advancing age, obesity, renal insufficiency, diabetes, and black
race) also portend risk of incident hypertension in HIV-infected
persons [12]. More interestingly, we observed that persons
who maintained a CD4 cell count above 500 cells/mm3 ap-
peared to be at lower risk for a subsequent diagnosis of hyper-
tension. Our data also suggest a possible association between
durable HIV VL suppression and lower incident hypertension
diagnoses among HIV-infected persons in our clinical cohort.
Table 3. Incidence Rates of Hypertension by Duration of Antiretroviral Therapy and Duration of Follow-up
Duration of ART
Number of
Events Person Years
Crude Incidence
Rate per 100 PY (95% CI)
Age-Adjusted Incidence
Rate per 100 PY (95% CI)
No ART 64 7298.7 0.88 (.66–1.10) 0.95 (.71–1.18)
Less than 2 y 192 5002.1 3.83 (3.29–4.37) 3.84 (3.30–4.38)
2–5 y 193 6932.0 2.78 (2.39–3.17) 2.72 (2.34–3.10)
More than 5 y 307 2723.3 11.27 (10.01–12.53) 11.16 (9.91–12.41)
Duration of follow-up
Less than 2 y 194 5866.3 3.31 (2.84–3.78) 3.37 (2.90–3.84)
2–5 y 189 8105.8 2.33 (2.00–2.67) 2.35 (2.01–2.69)
More than 5 y 373 7984.0 4.67 (4.20–5.14) 4.62 (4.15–5.09)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; PY, person years.
Table 4. Patient Characteristics Associated With Incident Hypertension
Characteristic
Bivariable Multivariable
IRR 95% CI IRR 95% CI P Value
Age, per 10 y increase 1.37 1.29–1.48 1.34 1.24–1.44 <.001
Female sex 1.11 .95–1.28 1.03 .84–1.26 .76
Race/ethnicity
Black 1.40 1.20–1.61 1.15 .97–1.37 .10
Hispanic 0.43 .29–0.65 0.54 .35–.84 .006
White Ref Ref
No insurance 0.90 .78–1.05 0.76 .62–.90 .003
BMI≥ 30 1.92 1.63–2.26 1.70 1.43–2.02 <.001
Serum creatinine≥ 1.4 (mg/dL) 1.23 1.06–1.43 1.36 1.16–1.61 <.001
Tobacco use 0.68 .58–0.78 0.73 .62–.86 <.001
Hyperlipidemia 0.97 .83–1.15 1.06 .89–1.27 .73
Diabetes 1.66 1.32–2.09 1.44 1.14–1.83 .002
HCV coinfection 0.98 .82–1.17 1.02 .81–1.30 .83
MSM 0.92 .81–1.07 1.18 .97–1.42 .10
IVDU 1.07 .87–1.32 1.20 .91–1.58 .20
Cocaine 1.12 .97–1.31 1.32 1.09–1.59 .004
Amphetamine 0.77 .49–1.20 1.01 .62–1.63 .97
CD4 nadir, cells/mm3
<200 0.90 .78–1.04 1.07 .92–1.27 .36
200–499 Ref Ref
≥500 1.00 .76–1.29 0.73 .53–1.01 .06
VL most recent, <400 copies/mL 0.83 .71–0.96 0.87 .74–1.03 .11
Any ART exposure 0.61 .47–0.80 1.19 .84–1.70 .33
History of PI exposure 0.69 .54–0.90 1.28 .93–1.77 .12
Incidence rate ratios (and associated confidence intervals, P-values) were derived using multivariable Poisson regression.
Bold represents statistically significant P-value <.05.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus; IRR, incident rate ratio; IVDU, intravenous drug use; MSM, men who have sex
with men; PI, protease inhibitor; Ref, reference; VL, viral load.
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Finally, over the course of the last decade, observations from
the clinical cohort show that there is a notable increase in
the incidence of new hypertension diagnoses among persons
living with HIV.
Although there was no definitive linear trend between CD4
nadir count and incident hypertension diagnoses, data from our
cohort suggest that persons who maintain CD4 counts above
500 cells/mm3 for the duration of infection have a lower inci-
dence of hypertension. These findings were independent of
other known risk factors for hypertension including black race,
obesity, renal insufficiency, and sex. Our observations are con-
sistent with findings reported by Manner and others in a
Norwegian clinical HIV cohort [13]. CD4 nadir, a biomarker
for the degree of HIV-associated immunosuppression and a
surrogate for the intensity of ongoing chronic immune activa-
tion and persistent inflammation, has been shown to be associ-
ated with cardiovascular outcomes in persons living with HIV
[14, 15]. Low CD4 nadir have been reported to be associated
with both increased subclinical atherosclerosis as assessed by
carotid intimal medial thickness and increased risk of myocar-
dial infarction in a large clinical cohorts [16]. Low CD4 nadirs
have also been suggested to be associated with the diagnosis of
left ventricular hypertrophy in asymptomatic HIV infected per-
sons, a condition for which hypertension is the preeminent risk
factor [17].
Though the etiology of essential hypertension is complex and
incompletely understood, a growing body of evidence suggests
that there may be an immunologic basis for this disease patho-
physiology [18, 19].Data from experimental mouse models have
shown that T-cells are essential to the development of angioten-
sin-II induced hypertension [20]. Experimental mouse models
have shown that on immune reconstitution of T-cell depleted
mice, their increase in blood pressure in response to angioten-
sin-II is restored. Interestingly, endothelial-dependent vasodila-
tation remained impaired and vascular superoxide levels were
increased compared to wild-type mice potentially predisposing
the reconstituted mice to subsequent hypertension [21]. Pro-
inflammatory cytokines like C-reactive protein (CRP) and in-
terleukin (IL)-6 are also elevated in HIV-infected persons with
low CD4 nadir [16, 22]. Elevated levels of CRP and IL-6 have
also been shown to be independently associated with hyperten-
sion in humans [23]. Most recently, investigators in Korea
showed that T-cell enumeration in persons with newly diag-
nosed hypertension revealed increased circulating CD28neg
CD57pos T-cells, a sign of T-lymphocyte aging [24]. Immuno-
senscence is a well-established consequence of chronic immune
activation known to occur at a much higher level in persons
with low CD4 nadirs compared to higher CD4 nadirs [14, 25,
26]. Although definitive human studies are needed, the current
state of evidence linking CD4 nadir with the risk of incident hy-
pertension is compelling. Our findings also suggest an association
between viral suppression and incident hypertension; however,
achieving viral suppression may be strongly associated with favor-
able health behaviors related to lower hypertension risk.
In this analysis, we also observed that the incidence rate of
hypertension continues to increase in the ART era. Although
the aging of HIV-infected population as a whole may account
for some of this observation, the age-standardized incidence
rates presented in our study indicate other potential explana-
tions for this trend. First, the lower rates of hypertension
in the earlier years of observation may be due to the higher
prevalence of severely immunosuppressed persons during that
period. The clinical association of AIDS- associated severe im-
munosuppression, low body weight and generally poor health
with low blood pressure is well established. This likely also ex-
plains the low incidence rates of hypertension among persons
not on ART. In addition, given the relative higher acuity of pa-
tients presenting to the clinic during that time period, there is a
possibility of underreporting during that time period that was
slowly reduced as more patients achieved clinical stability on
ART with each passing year On the cellular level, the potential
role of T-lymphocytes in the pathobiology of essential hyper-
tension further supports the observed lower incidence rates of
elevated blood pressure during that time period.
Another consideration is that persons with previously severe
immunosuppression and CD4 were returned to health often pre-
saged by a rapid gain in weight and other dynamic changes in
metabolism that may unmask longstanding predilections (genet-
ic, demographic, or behavioral) toward hypertension. As sup-
ported by our observations and the aforementioned reports,
immune reconstitution itself may be associated with a higher
risk of hypertension. Finally, our observation of an increase in
hypertension incidence rates may be a consequence of delayed
effects of metabolic adverse antiretroviral medications, including
early generation protease inhibitors and nucleoside reverse tran-
scriptase inhibitors (D4T, DDI, AZT, etc). This study did not ad-
dress the association between the chronologic distance between
exposure to these drugs and the incident diagnosis of hyperten-
sion, although will be addressed in future analyses.
We did not observe a definitive link between duration of ART
therapy, protease inhibitor exposure and incident hypertension
as indicated in previous reports [9, 12]. Although an association
was observed between hypertension incidence and duration of
ART exposure, this is likely confounded by duration of follow-
up time given the comparable results of our stratified analysis
on both variables (Table 3). Accordingly, the seemingly protec-
tive effect of ART on incident hypertension noted by our point
estimates is likely driven primarily by persons with less than 5
years of ART exposure and therefore hard to interpret (Table 4).
When ART exposure was considered as a binary variable in our
regression model, there was no clear association with incident
hypertension (IRR 1.19, 95% CI, .84–1.70, P-value = .33). Fur-
ther studies are needed to better define the relationship between
ART and hypertension incidence.
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This study has limitations. This study is an observational clin-
ical cohort, and therefore data on individual risk determinants
are dependent on the quality of clinical care documentation
at the time of the event. The definition of hypertension, the
outcome of interest, was strictly limited to physician documen-
tation and medical record review by the study team. We
acknowledge that this approach although practical may lead
to underreporting of hypertension since detection completely
depends on both clinician assessment and documentation. As
mentioned above, our study did not address the association of
hypertension with individual antiretroviral agents, highly rele-
vant given the current discourse of the cardiovascular risk pro-
file of newer protease inhibitors and recently re-emerging ART
agents like abacavir.
In conclusion, our data suggest that though risk determinants
for hypertension in uninfected persons also predict risk in per-
sons living with HIV, a history of severe HIV related immunosup-
pression and ongoing viremia may be independently associated
with hypertension as well. Though the differential risk of immune
vs conventional risk factors is still not well defined, it is clear that
further consideration must be given to the long-term deleterious
impact of immunosuppression, immune recovery and persistent
immune activation on vascular physiology. Our data also indicate
a continued increase in the incidence rate of hypertension in
HIV-infected persons, a concerning trend in light the novel rec-
ognition of people living with HIV as a high-CVD risk group.
Finally, our study suggests no clear association between protease
inhibitors, duration of exposure to ART, and the risk of incident
hypertension. Taken together, our findings present more evidence
in support of early ART for all persons with HIV and further em-
phasizes the importance of high quality CVD primary preventive
care in this high-risk population.
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